Granules India's arm gets USFDA’s nod for Lisdexamfetamine dimesylate chewable tablets

17 Dec 2024 Evaluate

Granules India’s wholly owned foreign subsidiary -- Granules Pharmaceuticals, Inc., has received approval from the U.S. Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Lisdexamfetamine Dimesylate Chewable Tablets. The approved drug is available in multiple strengths: 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, and 60 mg. 

This generic drug product has been determined to be bioequivalent (AB Rating) to the reference listed drug, Vyvanse Chewable Tablets by Takeda Pharmaceuticals USA Inc. Lisdexamfetamine dimesylate chewable tablets are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients aged six years and older, as well as Moderate to Severe Binge Eating Disorder (BED) in adults.

The company has received approval in the first review cycle, reflecting the company’s consistent focus on regulatory excellence and expedited product delivery. Lisdexamfetamine Dimesylate Chewable Tablets are currently published on the FDA Drug Shortages List, emphasizing their critical role in patient care. The company now holds 68 ANDA approvals, including 30 ANDAs from GPI.

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).


Granules India Share Price

592.50 2.80 (0.47%)
18-Dec-2024 14:13 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1803.00
Dr. Reddys Lab 1277.40
Cipla 1477.20
Lupin 2100.00
Zydus Lifesciences 983.25
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.